Oct 12 (Reuters) - BiVictriX Therapeutics PLC:
* EXTENDED SURVIVAL RATES REPORTED WITH BVX001 IN A PRE-CLINICAL MODEL OF ACUTE MYELOID LEUKAEMIA Source text for Eikon: Further company coverage:
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.5 GBX | 0.00% | 0.00% | +9.52% |
04-17 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
04-17 | BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment | MT |
Oct 12 (Reuters) - BiVictriX Therapeutics PLC:
* EXTENDED SURVIVAL RATES REPORTED WITH BVX001 IN A PRE-CLINICAL MODEL OF ACUTE MYELOID LEUKAEMIA Source text for Eikon: Further company coverage:
1st Jan change | Capi. | |
---|---|---|
+9.52% | 11.94M | |
+29.50% | 49.18B | |
+1.05% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.64% | 26.09B | |
-22.68% | 18.71B | |
+8.18% | 13.26B | |
+32.23% | 12.32B | |
-0.72% | 11.99B |